Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Changzhou Univ. TGR5 compound A10
- Development stage
- Preclinical
- Lead developer
- Changzhou University
01
Overview
Changzhou Univ. TGR5 compound A10: sourced facts only. name: "Taken together, we discovered two potent and selective TGR5 allosteric agonists A1 and A10, which could be employed as lead compounds to further study TGR5 allostery with potential antidiabetic effects." [PMID:41455205]; target: "Taken together, we discovered two potent and selective TGR5 allosteric agonists A1 and A10, which could be employed as lead compounds to further study TGR5 allostery with potential antidiabetic effects." [PMID:41455205]; developer: "School of Pharmacy, Changzhou University, Changzhou 213164, PR China." [PMID:41455205]; stage: "More importantly, both A1 and A10 exhibited significant glucose-lowering effects in the oral glucose tolerance test (OGTT) in mice." [PMID:41455205]
02
Targets
GPBAR1
Beyond the preview
Go deeper on Changzhou Univ. TGR5 compound A10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Changzhou Univ. TGR5 compound A10.